Hepcinat LP Tablet
- Manufacturer : Natco Pharma Ltd
- Equivalent Brands : MY Hep
- Generic Brands : Ledipasvir/ Sofosbuvir
Hepcinat-LP is a new recently-launched blockbuster from Natco Pharma Ltd (India). Hepcinat contains polymerase inhibitor sofosbuvir+ledipasvir which approved for the treatment of patients infected with hepatitis C genotype 1 and 4. Sofosbuvir & Ledipasvir is the first FDA-approved treatment protocol for HCV infection, which does not require interferon or ribavirin. In the clinical studies have proven extremely high success rate of sofosbuvir in couple with ledipasvir.
Hepcinat LP Tablets is combination of two hepatitis C virus (HCV) antiviral drugs in a single form. Each single tablet contains ledipasvir 90mg and sofosbuvir 400 mg.
Hepcinat-LP Tablet is a combination of two antiviral medicines: Ledipasvir and Sofosbuvir. They work by lowering the amount of hepatitis C virus in the body and removing the virus from the blood over a period of time.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Hepcinat-LP Tablet may be taken with or without food, but it is better to take it at a fixed time.
Often, people who are treating the Hepatitis C, with the help of Hepcinat LP, they face some common side effects which are mentioned below:
In more than 10% of the cases, people face severe headaches and general Fatigue.
People also experience nausea. 6% of people face it within 8 weeks of the dosage, 7% at 12 weeks and 9% within 24 weeks of the treatment.
One of the common side effects which is experienced by 7% of the patients is Diarrhoea.
Patients also face sleeping problems in 3,5,6 % of the cases.
Allergic reactions caused due to the ingredients of the tablet are very rare in patients.
The side effect when the Hepcinat LP treatment is taken by pregnant women is still unknown.
The main reason for why it is still unknown is that proper studies have not been conducted. However, the scientists have conducted various tests on laboratory rats to know the side effects of the generic drug. No effects on the fatal development was recorded at a maximum dose rate of the generic drug Hepcinat LP.
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Hepcinat-LP, especially:
This list is not complete. Other drugs may interact with ledipasvir and sofosbuvir, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Avoid using the medicine if you are allergic to Ledipasvir + Sofosbuvir combination or similar drugs.
Avoid consumption of alcohol as it may alter the absorption of Ledipasvir + Sofosbuvir combination.
Do not exceed the dose more than what is prescribed.
Do not stop using the medication abruptly unless instructed by the doctor. Stopping the medication suddenly may cause the illness to return.
Avoid Ledipasvir + Sofosbuvir combination during pregnancy or breastfeeding because the safe use of the drug is not yet established.
Be cautious while taking Ledipasvir + Sofosbuvir combination if you have any liver impairment and if you have to take the drug in combination with Amiodarone or Ribavirin.
Seek doctor’s advice before taking any other drug or herbal products while on Ledipasvir + Sofosbuvir combination.
You are advised not to take Ledipasvir + Sofosbuvir combination if it has passed the expiry date of the medicine printed on the pack.
the foil or packaging is torn or shows signs of tampering or there is discoloration.
Interaction with alcohol is unknown. Please consult your doctor.
Hepcinat-LP Tablet is probably safe to use during pregnancy.
Animal studies have shown low or no adverse effect on the foetus, however, there are limited human studies. Please consult your doctor.
Hepcinat-LP Tablet is probably safe to use during lactation. Limited human data suggests that the drug does not represent a significant risk to the baby.
Do not drive unless you are feeling well.
Hepcinat-LP Tablet, when taken together with other medicines for the treatment of hepatitis c infection, may produce dizziness, blurred vision and this may affect your ability to drive.
Hepcinat-LP Tablet should be used with caution in patients with severe kidney disease. Dose adjustment of Hepcinat-LP Tablet may be needed. Please consult your doctor.
Limited information is available on use of Hepcinat-LP Tablet in these patients. No dose adjustment is recommended in patients with mild to moderate kidney disease.
Hepcinat-LP Tablet is safe to use in patients with liver disease. No dose adjustment of Hepcinat-LP Tablet is recommended.
8 weeks: This treatment can be considered for naive patients without Cirrhosis who have pre-treatment HCV RNA < 6 million IU/mL.
12 weeks: For Naive patients with or without Cirrhosis.
12 weeks: For experienced patients without Cirrhosis those have failed treatment with either peginterferon alfa + ribavirin or an HCV protease inhibitor + peginterferon alfa + Ribavirin.
24 weeks: For experienced patients with Cirrhosis who have failed treatment with either peginterferon alfa + ribavirin or an HCV protease inhibitor + peginterferon alfa + Ribavirin.
Hepcinat-LP Tablet is used in the treatment of chronic hepatitis C virus (HCV) infection.
Hepcinat LP comprises Sofosbuvir which is used to treat chronic hepatitis C drug is excellent for treating 1, 2, 3 and 4 genotype. To achieve maximum benefit from the treatment, you should take Sofosbuvir together with other drugs. One tablet 400 mg Hepcinat LP Sofosbuvir. Taken one tablet per day. Preferably the tablet is orally taken while eating, drinking water. A proper and timely dosage is important
There are some obligatory steps you need to follow during the period of medication and otherwise as well.
Store it at room temperature, and in an airtight container. Keep away from children.